A Phase 1/2 Safety and Efficacy Study of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Nov 2018
At a glance
- Drugs Epacadostat (Primary) ; INCAGN 1876 (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Biosciences International
- 05 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Dec 2017 Status changed from not yet recruiting to recruiting.
- 15 Sep 2017 New trial record